Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TST005 in Locally Advanced or Metastatic Solid Tumors
NCT04958434Phase 1Terminated
- Sponsor
- Transcenta
- Start
- Jun 2021
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of TST005 in solid tumor (advanced stage) and HPV-associated malignant neoplasm (2 arms), sponsored by Transcenta. Primary endpoints: Maximum Tolerated Dose or Recommended Phase 2 Dose and Frequency and Severity of Adverse Events. Started Jun 2021; status: terminated.
02
Drugs
TST005
03
Conditions
solid tumor (advanced stage)HPV-associated malignant neoplasm
Beyond the preview
Go deeper on NCT04958434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958434.